Insider · CIK 0001657719
David O. Watson
officer
Files at APLS (Apellis Pharmaceuticals, Inc.). First filing Dec 20, 2023, latest Jan 23, 2026.
In brief
David O. Watson files SEC Form 4 as officer at APLS (Apellis Pharmaceuticals, Inc.). Since Dec 20, 2023, David O. Watson has reported 0 open-market buys worth $0 and 18 open-market sells worth $2.5M, the latest filed on Jan 23, 2026.
A track record needs three past buys with six months of prices behind them; David O. Watson has 0, so none is measured yet.
The newest scored trade: sold $170k of APLS on Jan 22, 2026, filed Jan 23, 2026, scored 41 (moderate). In the last 12 months: 0 buys worth $0 and 6 sells worth $697k.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 18
$0 bought, $2.5M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | Apellis Pharmaceuticals, Inc. | $170k 7,832 shares | -8% | - | |
| 37Weak | Apellis Pharmaceuticals, Inc. | $49k 2,475 shares | -3% | - | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | $128k 5,780 shares | -6% | - | |
| 5Weak | Apellis Pharmaceuticals, Inc. | $122k 5,000 shares | -5% | - | |
| 5Weak | Apellis Pharmaceuticals, Inc. | $100k 5,000 shares | -4% | - | |
| 21Weak | Apellis Pharmaceuticals, Inc. | $126k 5,000 shares | -4% | - | |
| 20Weak | Apellis Pharmaceuticals, Inc. | $122k 5,000 shares | -4% | - | |
| 58Moderate | Apellis Pharmaceuticals, Inc. | $523k 20,000 shares | -29% | - | |
| 14Weak | Apellis Pharmaceuticals, Inc. | $139k 5,000 shares | -4% | - | |
| 13Weak | Apellis Pharmaceuticals, Inc. | $98k 5,000 shares | -4% | - | |
| 5Weak | Apellis Pharmaceuticals, Inc. | $94k 5,000 shares | -4% | - | |
| 34Weak | Apellis Pharmaceuticals, Inc. | $140k 5,569 shares | -4% | - | |
| 30Weak | Apellis Pharmaceuticals, Inc. | $21k 695 shares | -0% | - | |
| 40Moderate | Apellis Pharmaceuticals, Inc. | $101k 3,323 shares | -2% | - | |
| 38Weak | Apellis Pharmaceuticals, Inc. | $66k 2,201 shares | -2% | - | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | $143k 4,965 shares | -4% | - | |
| 34Weak | Apellis Pharmaceuticals, Inc. | $171k 5,000 shares | -4% | - | |
| 20Weak | Apellis Pharmaceuticals, Inc. | $223k 3,905 shares | -4% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 22, 2026 | APLS Apellis Pharmaceuticals, Inc. | 7,832 0.01% of outstanding | $170k | Jan 22, 2026 | $400k |
| Jan 20, 2026 | APLS Apellis Pharmaceuticals, Inc. | 2,475 0.00% of outstanding | $49k | Jan 20, 2026 | $351k |
| Jan 13, 2026 | APLS Apellis Pharmaceuticals, Inc. | 5,780 0.00% of outstanding | $128k | Jan 13, 2026 | $349k |
| Dec 16, 2025 | APLS Apellis Pharmaceuticals, Inc. | 5,000 0.00% of outstanding | $122k | Dec 16, 2025 | $348k |
| Nov 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | 5,000 0.00% of outstanding | $100k | Nov 17, 2025 | $387k |
| Oct 16, 2025 | APLS Apellis Pharmaceuticals, Inc. | 5,000 0.00% of outstanding | $126k | Oct 16, 2025 | $358k |
| Sep 16, 2025 | APLS Apellis Pharmaceuticals, Inc. | 5,000 0.00% of outstanding | $122k | Sep 16, 2025 | $331k |
| Sep 10, 2025 | APLS APELLIS PHARMACEUTICALS, INC | 20,000 0.02% of outstanding | $523k | Sep 10, 2025 | $331k |
| Aug 18, 2025 | APLS Apellis Pharmaceuticals, Inc. | 5,000 0.00% of outstanding | $139k | Aug 18, 2025 | $192k |
| Jul 16, 2025 | APLS Apellis Pharmaceuticals, Inc. | 5,000 0.00% of outstanding | $98k | Jul 16, 2025 | $94k |
| Jun 16, 2025 | APLS Apellis Pharmaceuticals, Inc. | 5,000 0.00% of outstanding | $94k | Jun 16, 2025 | none |
| Mar 5, 2025 | APLS APELLIS PHARMACEUTICALS, INC | 5,569 0.00% of outstanding | $140k | Mar 5, 2025 | $171k |
| Jan 29, 2025 | APLS Apellis Pharmaceuticals, Inc. | 695 0.00% of outstanding | $21k | Jan 29, 2025 | $312k |
| Jan 22, 2025 | APLS Apellis Pharmaceuticals, Inc. | 3,323 0.00% of outstanding | $101k | Jan 22, 2025 | $211k |
| Jan 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | 2,201 0.00% of outstanding | $66k | Jan 17, 2025 | $145k |
| Jan 13, 2025 | APLS Apellis Pharmaceuticals, Inc. | 5,056 0.00% of outstanding | $145k | Jan 13, 2025 | none |
| Dec 11, 2024 | APLS APELLIS PHARMACEUTICALS, INC | 5,000 0.00% of outstanding | $171k | Dec 11, 2024 | none |
| Dec 19, 2023 | APLS Apellis Pharmaceuticals, Inc. | 3,905 0.00% of outstanding | $223k | Dec 19, 2023 | none |
Transactions
The newest 50 of 51 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | UTender of shares Common Stock | -144,517 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | UTender of shares Common Stockindirect: Indirect Owner (Custodial Account for minor children) | -10,000 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | UTender of shares Common Stockindirect: Indirect Owner (The David O. Watson Irrevocable Trust of 2023) | -50,136 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +41,250 | - | - | 41,250 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -41,250 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +28,508 | - | - | 28,508 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -28,508 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +27,993 | - | - | 27,993 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -27,993 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +55,986 | - | - | 55,986 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -55,986 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -32,072 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -55,986 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -11,874 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -6,001 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -7,363 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -82,500 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -14,000 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -50,974 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -38,250 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -45,000 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -37,708 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -34,533 | - | - | 0 | May 14, 2026 |
| Jan 28, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +55,986 | $0.00 | $0 | 144,517 | Jan 30, 2026 |
| Jan 22, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -7,832 | $21.77 | $170k | 88,531 | Jan 23, 2026 |
| Jan 20, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,475 | $19.79 | $49k | 96,363 | Jan 21, 2026 |
| Jan 13, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -5,780 | $22.19 | $128k | 98,838 | Jan 15, 2026 |
| Jan 7, 2026 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +888 | $14.95 | $13k | 104,618 | Jan 9, 2026 |
| Jan 7, 2026 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -888 | $0.00 | $0 | 14,000 | Jan 9, 2026 |
| Dec 16, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $24.49 | $122k | 103,730 | Dec 18, 2025 |
| Nov 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $20.06 | $100k | 108,730 | Nov 18, 2025 |
| Oct 16, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $25.22 | $126k | 113,730 | Oct 17, 2025 |
| Sep 16, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $24.34 | $122k | 118,730 | Sep 18, 2025 |
| Sep 10, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: Indirect Owner (The David O. Watson Irrevocable Trust of 2023) | -20,000 | $26.17 | $523k | 50,136 | Sep 12, 2025 |
| Aug 18, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $27.80 | $139k | 123,730 | Aug 19, 2025 |
| Jul 16, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $19.55 | $98k | 128,730 | Jul 18, 2025 |
| Jun 16, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $18.77 | $94k | 133,730 | Jun 18, 2025 |
| Jun 9, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +82,500 | $19.39 | $1.6M | 82,500 | Jun 11, 2025 |
| Mar 4, 2025 | APLS Apellis Pharmaceuticals, Inc. | GGift Common Stockindirect: Indirect Owner (The Watson Education Trust) | -6,667 | $0.00 | $0 | 0 | Mar 6, 2025 |
| Mar 4, 2025 | APLS Apellis Pharmaceuticals, Inc. | GGift Common Stockindirect: Indirect Owner (Custodial Account for Son) | +6,667 | $0.00 | $0 | 10,000 | Mar 6, 2025 |
| Mar 5, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -5,569 | $25.10 | $140k | 138,730 | Mar 6, 2025 |
| Jan 29, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -695 | $29.52 | $21k | 144,299 | Jan 30, 2025 |
| Jan 22, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -3,323 | $30.43 | $101k | 144,994 | Jan 23, 2025 |
| Jan 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,201 | $29.96 | $66k | 105,555 | Jan 21, 2025 |
| Jan 21, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +42,762 | $0.00 | $0 | 148,317 | Jan 21, 2025 |
| Jan 13, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,965 | $28.70 | $143k | 107,756 | Jan 14, 2025 |
| Dec 11, 2024 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -5,000 | $34.24 | $171k | 112,721 | Dec 13, 2024 |
| Dec 19, 2023 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Common Stock | +7,905 | $13.85 | $109k | 93,658 | Dec 20, 2023 |
| Dec 19, 2023 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,605 | $57.00 | $91k | 92,053 | Dec 20, 2023 |
| Dec 19, 2023 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,300 | $57.38 | $132k | 89,753 | Dec 20, 2023 |
50 of 51 rows shown.
Questions about David O. Watson
Answered from the filings on this page, as of the latest one.
Is David O. Watson buying or selling?
In the last 12 months David O. Watson reported 0 open-market buys worth $0 and 6 open-market sells worth $697k on SEC Form 4; the latest was sold $170k of APLS on Jan 22, 2026. Grants, option exercises and tax withholding are not counted.
How did David O. Watson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David O. Watson has 0.
Where does David O. Watson file Form 4?
David O. Watson has filed Form 4 at APLS (Apellis Pharmaceuticals, Inc.) as General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.